Felipe Batalini, D. Gulhan, V. Mao, Madeline Polak, E. Winer, E. Mayer, U. Matulonis, P. Konstantinopoulos, P. J. Park, G. Wulf
{"title":"156:突变特征3预测奥拉帕尼加布帕利西布治疗三阴性乳腺癌和高级别浆液性卵巢癌的疗效","authors":"Felipe Batalini, D. Gulhan, V. Mao, Madeline Polak, E. Winer, E. Mayer, U. Matulonis, P. Konstantinopoulos, P. J. Park, G. Wulf","doi":"10.1158/1538-7445.AM2021-156","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73617,"journal":{"name":"Journal of bioinformatics and systems biology : Open access","volume":"507 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer\",\"authors\":\"Felipe Batalini, D. Gulhan, V. Mao, Madeline Polak, E. Winer, E. Mayer, U. Matulonis, P. Konstantinopoulos, P. J. Park, G. Wulf\",\"doi\":\"10.1158/1538-7445.AM2021-156\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73617,\"journal\":{\"name\":\"Journal of bioinformatics and systems biology : Open access\",\"volume\":\"507 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of bioinformatics and systems biology : Open access\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.AM2021-156\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of bioinformatics and systems biology : Open access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.AM2021-156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer